Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723990 | 1.00 | PIKFYVE (1.00) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL30090615 | 1.00 | PIKFYVE (1.00) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL30591068 | 1.00 | PIKFYVE (1.00) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL16756032 | 0.89 | PIKFYVE (0.80) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL16756035 | 0.89 | PIKFYVE (0.80) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL16200790 | 0.88 | PIKFYVE (0.79) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL16756030 | 0.88 | PIKFYVE (0.78) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL16756028 | 0.88 | PIKFYVE (0.78) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL15902413 | 0.87 | PIKFYVE (0.77) | PIKFYVEMEN1MAPTKMT2APSMD14 | |
| SCHEMBL15902411 | 0.87 | PIKFYVE (0.77) | PIKFYVEMEN1MAPTKMT2APSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9028796-B2 | Materials and methods useful to induce cell death via methuosis | THE UNIVERSITY OF TOLEDO (US) | 2015-05-12 | — | — | US | claimed |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | THE UNIVERSITY OF TOLEDO (US) | 2014-10-30 | — | — | US | claimed |
| WO-2012145069-A2 | MATERIALS AND METHODS USEFUL TO INDUCE CELL DEATH VIA METHUOSIS | THE UNIVERSITY OF TOLEDO (US) | 2012-10-26 | — | — | WO | claimed |
| CN-117731689-A | Application of MOMIPP combined with LPS in preparation of pharmaceutical preparation for inducing immune cell death | 山东大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-9061994-B1 | Materials and methods useful to induce vacuolization, cell death, or a combination thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-04 | — | — | US | disclosed |
| US-9028796-B2 | Materials and methods useful to induce cell death via methuosis | THE UNIVERSITY OF TOLEDO (US) | 2015-05-12 | — | — | US | disclosed |
| US-9023871-B2 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | THE UNIVERSITY OF TOLEDO (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2012145069-A2 | MATERIALS AND METHODS USEFUL TO INDUCE CELL DEATH VIA METHUOSIS | THE UNIVERSITY OF TOLEDO (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | BECN1, BAD, BAX | PIKFYVE 543/4885MEN1 1465/4885MAPT 2529/4885 |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | BECN1, BAD, BAX | PIKFYVE 543/4885MEN1 1465/4885MAPT 2529/4885 |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | PIKFYVE 2188/4885MEN1 1198/4885MAPT 4340/4885 |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | MCL1, BAX, BCL2 | PIKFYVE 1846/4885MEN1 2167/4885MAPT 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.